Aim immunotech announces abstracts from roswell park comprehensive cancer center accepted for presentation in a late-breaking poster session at the aacr 2022 annual meeting

Ocala, fla., march 09, 2022 (globe newswire) -- aim immunotech inc. (nyse: american aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, announced today that oncology experts from roswell park comprehensive cancer center will present findings from two ongoing clinical studies involving an aim immunotech inc. drug candidate, ampligen® (also known as rintatolimod) at the american association for cancer research (aacr) annual meeting 2022, being held april 8-13, 2022, in new orleans, louisiana.
AIM Ratings Summary
AIM Quant Ranking